TIMING-ICP: Timing of Invasive Intracranial Pressure Monitoring Between Neurosurgeons and Intensive Care Physicians

Sponsor
Università degli Studi di Brescia (Other)
Overall Status
Recruiting
CT.gov ID
NCT05045105
Collaborator
(none)
64
18
12.2
3.6
0.3

Study Details

Study Description

Brief Summary

Invasive intracranial pressure monitoring takes on essential importance in patients with traumatic brain injury and in all cerebral pathologies in which intracranial hypertension is the main cause of death.

Prolonged Intracranial Hypertension has been related to poor outcome and its occurrence has therefore to be assessed as soon as possible.

Invasive intracranial pressure monitoring performed by placing an intracerebral catheter is currently the gold standard technique for continuous ICP invasive monitoring. This maneuver has usually been performed by neurosurgeons, but recently this procedure has more often been carried out by intensivists, at the bedside.

Management of intracranial pressure handling and treatment is currently achieved by joint decisions between neurosurgeons and intensive care physicians, but differences in logistic matters and in the executive availability could impact on the dose of intracranial pressure to which patient is exposed.

The aim of this study is to compare timing of invasive intracranial pressure monitoring placement performed by intensive care physicians and neurosurgeons and to detect possible differences in the incidence of complications between the two groups.

Condition or Disease Intervention/Treatment Phase
  • Other: Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication

Detailed Description

This perspective, multicentric and observational study will enroll patients at risk for developing intracranial hypertension, for whom it is thought invasive ICP monitoring is crucial for achieving the most appropriate treatment.

Indication to invasive ICP monitoring and its modalities will be set through a joint decision between neurosurgeons and intensive care physician, which will be led by clinical and instrumental data.

This study will be carried out in Intensive Care Unit and in Neurosurgery department.

Sample size assessment:

Sample size assessment has been performed by Monte Carlo simulation (B=500). Assuming a timing decrease (T2-T1) of 20 minutes in the procedure carried out by an intensivist compared to a neurosurgeon, with a mean time of 100 minutes, a standard deviation between center and intra-center of 10 minutes, 16 centers, each one with the same number of patients and a balance 1:1 between the two groups (intensivist:neurosurgeon), a total number of 64 patients (32 treated by intensivists and 32 by neurosurgeons), it allows us to evaluate the interest effect with a power of at least 95%, and a significance level of 5%.

This elevated power has been decided according to the simplicity of the assumed design (same number of entities and conditions for center) and not evaluable in his real configuration.

Statistical analysis plan:

Delta time in the placement of invasive ICP monitoring is assumed as T2-T1, declared in minutes.

Typology operator (neurosurgeon vs intensivist) impact on delta time will be evaluated through a multilevel model elaborated with a linear mixed model. The model will assume the center in which the maneuver is carried out as clustering factor. The place where the maneuver is carried out (intensive care unit vs operating room) and the confidence in performing the procedure (routine vs sporadic, defined as less than 5 times a year) will be assumed as covariates.

The incidence of complications, valued as a binary variable, will be evaluated through logistic model GLMM (generalized linear mixed model) with the organization exposed in the dedicated data element.

Timings are defined as:
  • T0: suspect of pathology at risk for developing intracranial hypertension

  • T1: neurointensive and neurosurgical indication to invasive ICP monitoring (it can be the time when brain CT is performed or, in the absence of a brain CT, the time at which indication to invasive ICP monitoring is stated)

  • T2: skin incision at skull for BOLT/EVD placement

Place of positioning:

The place (intensive care unit or operating room) where the procedure is carried out must be declared.

Study Design

Study Type:
Observational
Anticipated Enrollment :
64 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Timing of Invasive Intracranial Pressure Monitoring Between Neurosurgeons and Intensive Care Physicians
Actual Study Start Date :
Apr 27, 2021
Anticipated Primary Completion Date :
May 3, 2022
Anticipated Study Completion Date :
May 3, 2022

Arms and Interventions

Arm Intervention/Treatment
ICU physicians

Intensive Care physicians who will apply the method of invasive insertion of the intracerebral catheter for ICP monitoring

Other: Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication
Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication and complications related to the maneuver between the two cohorts will be evaluated and compared.
Other Names:
  • Complications related to the maneuver between the two cohorts
  • Neurosurgeons

    Neurosurgeons who will apply the method of invasive insertion of the intracerebral catheter for ICP monitoring

    Other: Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication
    Time necessary for ICP catheter placement by Intensive Care Physician vs Neurosurgeon following indication and complications related to the maneuver between the two cohorts will be evaluated and compared.
    Other Names:
  • Complications related to the maneuver between the two cohorts
  • Outcome Measures

    Primary Outcome Measures

    1. To compare timing of invasive intracranial pressure monitoring performed by intensive care physicians and neurosurgeons [The time frame, will be from when the suspicion of a potential increase in ICP is given to when the actual skin incision for the insertion of the invasive catheter placement is performed. From indication up to 5 hours.]

      The time frame, which also represents the main outcome of this study, is defined as the time-difference between the moment when indication of invasive ICP monitoring is given and the moment when the skin incision is performed for ICP monitoring placement.

    Secondary Outcome Measures

    1. Comparative evaluation of post-procedural complications between intensivists and neurosurgeons [procedure to hospital discharge (in case of malfunction of the catheter, time is up to 12 hours after placement)]

      Comparative evaluation of post-procedural complications (meningitis, catheter-placement related bleedings, wrong placement) between intensivists and neurosurgeons

    2. Length of ICU stay [ICU admission to discharge, up to 30 days]

      Length of ICU stay

    3. length of hospital stay [hospital admission to discharge, up to 30 days]

      length of hospital stay

    4. duration of mechanical ventilation [from initiation of mechanical ventilation to weaning from the ventilator, up to 30 days.]

      duration of mechanical ventilation

    5. Glasgow Outcome Score at 3 months [3 months after the acute event]

      Glasgow Outcome Score

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • All patients with acute cerebral pathology with urgent indication to invasive intracranial pressure monitoring (intraparenchymal and intraventricular)

    • Age greater than or equal to 18 years

    Exclusion Criteria:
    • Patients in whom indication to intraventricular catheter placement is stated for reasons other than the need of ICP monitoring (e.g. CSF drainage)

    • Patients in whom indication to invasive intracranial pressure monitoring is not an urgent request

    • Patients in whom a significative coagulation disorder is a contraindication for procedure

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Ospedale "M. Bufalini", Intensive Care Unit (U.O. Anestesia e Rianimazione), Neurosurgery Unit (U.O. Neurochirurgia) Cesena Forlì-Cesena Italy 47521
    2 Azienda Socio Sanitaria Territoriale Ovest Milanese (Neurosurgery Unit) Legnano Milano Italy 20025
    3 Ospedale Papa Giovanni XXIII, Intensive Care Unit (U.O. Anestesia e rianimazione 2), Neurosurgery Unit (U.O. Neurochirurgia) Bergamo Italy 24127
    4 Spedali Civili di Brescia, Neurosurgery Unit (U.O. Neurochirugia) Brescia Italy 25123
    5 Spedali Civili, Neuro Critical Care Unit (U.O. Anestesia e Rianimazione 2) Brescia Italy 25123
    6 Azienda Ospedaliera Sant'Anna e San Sebastiano di Caserta (Neurosurgery Unit) Caserta Italy 81100
    7 Ospedale Sant'Anna di Como, Intensive Care Unit (U.O. Anestesia e Rianimazione 2), Neurosurgery Unit (U.O. Neurochirurgia) Como Italy 22100
    8 Ospedale Policlinico San Martino (Neurosurgery Unit) Genova Italy 16132
    9 Ospedale Santa Maria Goretti (Neurosurgery Unit) Latina Italy 04100
    10 Ospedale A. Manzoni (Intensive Care Unit and Neurosurgery Unit) Lecco Italy 23900
    11 Ospedale Civile di Baggiovara (Neurosurgery Unit) Modena Italy 41126
    12 Ospedale Santa Maria di Loreto Nuovo, Intensive Care Unit (U.O.C. di Terapia Intensiva e Rianimazione), Neurosurgery Unit (U.O.C. Neurochirurgia) Napoli Italy 80142
    13 Azienda Ospedale Università Padova (Neurosurgery Unit) Padova Italy 35128
    14 Policlinico San Matteo, Intensive Care Unit (U.O. Anestesia e rianimazione 2), Neurosurgery Unit (U.O. Neurochirurgia) Pavia Italy 27100
    15 Policlinico Universitario Agostino Gemelli (Neurosurgery unit) Roma Italy 00168
    16 Azienda Ospedaliera Città della Salute e della Scienza, Intensive Care Unit (U.O. Anestesia e Rianimazione), Neurosurgery Unit (U.O. Neurochirurgia) Torino Italy 10126
    17 Presidio Ospedaliero Universitario Santa Maria della Misericordia, Intensive Care Unit (U.O. Anestesia e Rianimazione), Neurosurgery Unit Udine Italy 33100
    18 Azienda Ospedaliera Universitaria Integrata Verona (Neurosurgery Unit) Verona Italy 37126

    Sponsors and Collaborators

    • Università degli Studi di Brescia

    Investigators

    • Principal Investigator: Frank Rasulo, Università degli Studi di Brescia

    Study Documents (Full-Text)

    More Information

    Publications

    Responsible Party:
    Dr. Frank Rasulo, Associate Professor in Anesthesiology and Intensive Care, Università degli Studi di Brescia
    ClinicalTrials.gov Identifier:
    NCT05045105
    Other Study ID Numbers:
    • NP4628
    First Posted:
    Sep 16, 2021
    Last Update Posted:
    Sep 16, 2021
    Last Verified:
    Sep 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 16, 2021